Goldman Sachs Maintains Neutral on Calumet, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 60.3%

Neg 0% Neu 0% Pos 60.3%

Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $36 to $40.